Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Pill Clear all
Not listed Not applicable Interventional

Ingestion of Simethicone After Capsule Ingestion and Its Impact on Quality of Video Capsule Endoscopy- a Pilot Study

NCT03166605
View directory record Official record
Conditions
Video Capsule Endoscopy
Interventions
Simethicone
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial

NCT00474851
View directory record Official record
Conditions
Endometriosis
Interventions
Norethindrone acetate + estrogens, norethindrone acetate + placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 22 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 3 Interventional

Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)

NCT01426256
View directory record Official record
Conditions
Cystic Fibrosis, Respiratory Tract Infections
Interventions
Cholecalciferol
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
16 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 30, 2026, 4:26 PM EDT
Withdrawn Not applicable Interventional

Impact of the Number of Opiates Prescribed on Post Cesarean Pain Control

NCT03175653
View directory record Official record
Conditions
Post-operative Pain Control
Interventions
Oxycodone Pill A, Oxycodone Pill B
Other
Lead sponsor
Mount Carmel Health System
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Results available

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

NCT01087736
View directory record Official record
Conditions
PTSD, Alcohol Abuse, Alcoholism
Interventions
Topiramate, Placebo administration
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome

NCT01071044
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Cognitive Impairments
Interventions
Lisdexamfetamine Dimesylate, Placebo "30, 50 or 70 mg"
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Not applicable Interventional Results available

Zinc & Bone Health in Thalassemia: The Think Zinc Study

NCT00459732
View directory record Official record
Conditions
Thalassemia
Interventions
Zinc, Placebo
Dietary Supplement
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
6 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Oakland, California • San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IMProving Executive Function Study

NCT03187353
View directory record Official record
Conditions
Cognitive Impairment, RRSO
Interventions
Lisdexamfetamine, Placebo oral capsule
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
35 Years to 58 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Results available

Validation of Dyskinesia Rating Scales

NCT01071395
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Amantadine, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Not applicable Interventional Results available

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease

NCT00323258
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
oral education & written tips for remembering medications, pill box, pocket medication card, sharing information with community pharmacist, Medication use evaluations by community pharmacist, informing physician if patient has stopped a medication, Routine discharge counseling, Letter to physician/discharge summary
Behavioral · Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Chantix on Relapse Prevention for Smoking Cessation

NCT00948649
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Placebo, Varenicline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional

Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia

NCT01868750
View directory record Official record
Conditions
Thyroid Nodules, Hypocalcemia
Interventions
Calcitriol, Control Pill
Dietary Supplement
Lead sponsor
David Shonka, MD
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 30, 2026, 4:26 PM EDT
Terminated Phase 2 Interventional Results available

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

NCT04899921
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Troriluzole, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 30, 2026, 4:26 PM EDT
Withdrawn Phase 2 Interventional

Rifaximin Treatment of Papulopustular Rosacea

NCT01359228
View directory record Official record
Conditions
Rosacea
Interventions
Rifaximin (XIFAXAN), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Paxil Use in Menopausal Women

NCT00225914
View directory record Official record
Conditions
Menopause
Interventions
Paroxetine, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

NCT01953432
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Not applicable Interventional Results available

Eplerenone for the Treatment of Central Serous Chorioretinopathy

NCT01990677
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
25mg Eplerenone, Placebo
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Cherry Hill, New Jersey • Marlton, New Jersey • Mays Landing, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 30, 2026, 4:26 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

NCT01471964
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
Interventions
MLN8237 and Erlotinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

NCT01418209
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Disturbance
Interventions
Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Chestnut Hill, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Baclofen Effects on Marijuana Dependence

NCT02011516
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Baclofen, Psychosocial, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Results available

Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss

NCT04701333
View directory record Official record
Conditions
Lactation Suppressed
Interventions
Cabergoline 1 MG, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 30, 2026, 4:26 PM EDT
Not listed Phase 2 Interventional

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

NCT02791958
View directory record Official record
Conditions
Hypertension
Interventions
Cardiovascular Fixed Dose Combination Pill AAR, Atorvastatin 40 mg, Ramipril 10 mg
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years to 74 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 30, 2026, 4:26 PM EDT
Withdrawn Phase 4 Interventional

Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

NCT00781755
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
varenicline, Adaptation of Motivational Interviewing
Drug · Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Brockton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 30, 2026, 4:26 PM EDT